Product Information

LITHIUM CARBONATE ER 300 MG TB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1865 per EA under NDC 64980020501. Its NADAC has been published 546 times since Jun 8, 2016.

FDA first approved this application on Jul 27, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

LITHIUM CARBONATE ER 300 MG TB

Lithium Carbonate
$0.1865per EA

Strength

300 mg/1

NDC

64980020501

Classification

Generic

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

LITHIUM CARBONATE

Approval Type

Generic (ANDA)

FDA Application

ANDA204779

FDA Approved

7/27/2015

TE Code

AB

On Market Since

3/23/2016

Pharmacological Classes

Price Statistics

The NADAC for LITHIUM CARBONATE ER 300 MG TB has been published 546 times since Jun 8, 2016, and over the history we have for it it has declined 6.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1865 per EA
All-time high$0.2271 (Nov 13, 2024)
All-time low$0.1260 (Dec 21, 2022)
52-week high$0.2097
52-week low$0.1865
Median price$0.1545
Average price$0.1638
Largest weekly change+33.8% (Jun 19, 2024)
Weeks tracked546
Tracking sinceJun 8, 2016

Price History

1W

-3.1%

1M

-5.0%

3M

-4.8%

6M

-10.1%

1Y

-10.3%

3Y

+27.1%

5Y

+11.7%

All

-6.7%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of LITHIUM CARBONATE ER 300 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for LITHIUM CARBONATE ER 300 MG TB, manufactured by Rising Pharma Holdings Inc., is $0.1865 per EA (NDC 64980020501), effective Nov 18, 2026.

How has the price of LITHIUM CARBONATE ER 300 MG TB changed over time?

Over the history we have for it, the NADAC for LITHIUM CARBONATE ER 300 MG TB has declined 6.7%. It has been tracked across 546 weekly CMS publications since Jun 8, 2016.

What are the highest and lowest recorded NADAC prices for LITHIUM CARBONATE ER 300 MG TB?

Since Jun 8, 2016, the NADAC for LITHIUM CARBONATE ER 300 MG TB has ranged from a low of $0.1260 (Dec 21, 2022) to a high of $0.2271 (Nov 13, 2024), with a median of $0.1545 per EA.

Are there cheaper alternatives to LITHIUM CARBONATE ER 300 MG TB?

2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LITHIUM CARBONATE ER 300 MG TB in a comparable dosage form, but none are currently priced below it.

Who manufactures LITHIUM CARBONATE ER 300 MG TB?

LITHIUM CARBONATE ER 300 MG TB (NDC 64980020501) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.